Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 575 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Nonalcoholic Steatohepatitis Clear all

Conditions: Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions: MN-001; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Coronado, California • La Jolla, California • Seattle, Washington

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: HU6, Placebo; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 28 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: NAFLD
Interventions: Standard of care plus sugar-reduction education; Other
Lead sponsor: University of Southern California; Other
Eligibility: 12 Years to 18 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Nonalcoholic Steatohepatitis, Liver Diseases
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: NAFLD, NASH
Interventions: LiverFASt; Diagnostic Test
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 80 Years
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Nonalcoholic Steatohepatitis
Interventions: Proglumide; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Liver Diseases
Interventions: Pioglitazone, Vitamin E, Matching placebo; Drug · Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Fish Oil Supplementation, Placebo Supplementation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Placebo, Resmetirom; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 76
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more

Conditions: Non-Alcoholic Steatohepatitis (NASH)
Interventions: GR-MD-02, Placebo; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: NAFLD
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions: Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Spironolactone 100mg, Placebo oral capsule; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Aramchol free acid, Placebo; Drug
Lead sponsor: Galmed Research and Development, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Arlington, Texas

Conditions: Nonalcoholic Steatohepatitis
Interventions: SGM-1019, Placebo; Drug
Lead sponsor: Second Genome; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 10
States / cities: Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more

Conditions: Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions: AZD4831, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 13 more

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: AXA1125, Placebo; Drug
Lead sponsor: Axcella Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Tirzepatide, Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 141
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more

Conditions: NASH, Fatty Liver, NAFLD, Weight Loss
Interventions: Noom Healthy Weight Program; Behavioral
Lead sponsor: Noom Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Interventions: Usual Care then FitBit, FitBit then Usual Care; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: NASH With Fibrosis, MASH With Fibrosis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 198
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more

Conditions: Fatty Liver, Nonalcoholic, Liver Diseases
Interventions: Ketogenic Diet, Standard Weight Loss Diet; Other
Lead sponsor: Marc Goodman; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: BIO89-100; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more

Search by objective public record fields.

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

Healthy Eating Through Reduction Of Excess Sugar

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

Safety and Tolerability of Oral Proglumide for NASH

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Copeptin and Nonalcoholic Fatty Liver Disease

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Spironolactone Therapy In Young Women With NASH

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

A Study in Participants With Non-cirrhotic NASH With Fibrosis

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Effects of Online App Weight Loss Programs on Liver Health in Obese Adults

Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Ketogenic Diet in Non-alcoholic Fatty Liver Disease

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

A Study to Identify and Characterize LAL-D Patients in High-risk Populations